Novartis is a Swiss multinational pharmaceutical company headquartered in Basel and formed in 1996 through the merger of Ciba-Geigy and Sandoz. The company focuses on innovative medicines and is listed on the SIX Swiss Exchange under NOVN.
Novartis will acquire Pikavation Therapeutics for up to $3 billion to gain its PI3Kα inhibitor programs, led by SNV4818 for metastatic breast cancer. The deal includes $2 billion upfront and up to $1 billion in milestones, with completion expected in first half 2026. SNV4818 is designed to selectively target mutated PI3Kα while sparing healthy cells.
Over 20 pharmaceutical companies are developing therapies for HER2-positive gastric cancer, with multiple Phase III trials launched in March 2026 testing novel combination treatments for advanced disease.
Multiple pharmaceutical companies have initiated clinical trials for metastatic castration-resistant prostate cancer in February 2026, with over 180 companies developing 200+ pipeline therapies. Studies include combination therapies and novel drug candidates targeting advanced disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07779460 |
A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice |
RECRUITING | |
| NCT07775924 |
A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus |
NOT_YET_RECRUITING | PHASE2 |
| NCT07770074 |
A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients |
NOT_YET_RECRUITING | |
| NCT07768371 |
A 52-week Study of Remibrutinib in IgE-mediated Food Allergy |
NOT_YET_RECRUITING | PHASE3 |
| NCT07767890 |
A Study of the Safety and Effectiveness of Onasemnogene Abeparvovec (Zolgensma) Intrathecal Injection in Spinal Muscular Atrophy Patients |
NOT_YET_RECRUITING | |
| NCT07767877 |
A Study of Clinical Practice and Real-world Care of Patients Treated With mTOR, PI3K, and MEK Inhibitors for Extracranial Vascular Anomalies |
NOT_YET_RECRUITING | |
| NCT07760714 |
A Real-World Study of Treatment Patterns, Tolerability and Effectiveness of CDK4/6 Inhibition in HR+, HER2-negative Metastatic Breast Cancer Patients |
COMPLETED | |
| NCT07757048 |
A Study of Treatment Patterns and Real-World Outcomes in IgA Nephropathy Patients in the United States |
COMPLETED | |
| NCT07748624 |
A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period |
NOT_YET_RECRUITING | PHASE2 |
| NCT07743281 |
A Study of Treatment Patterns and Annualized Relapse Rate in Multiple Sclerosis Patients Who Escalate Versus Continue Disease-Modifying Therapies Following Relapse |
COMPLETED |
